BMY
Bristol-Myers Squibb Company
NYSE: BMY · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$57.59
-1.15% today
Updated 2026-04-29
Market cap
$119.87B
P/E ratio
16.97
P/S ratio
2.49x
EPS (TTM)
$3.46
Dividend yield
4.22%
52W range
$41 – $62
Volume
11.8M
Bristol-Myers Squibb Company (BMY) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+6.6%
Last 4 quarters
Revenue YoY growth
+1.3%
Most recent quarter
EPS YoY growth
-24.6%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+4.0%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+8.1%
2025-10-30
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-05 | $1.26 | -22.7% | $57.62 | $61.99 | +7.6% |
| 2025-10-30 | $1.63 | -3.6% | $42.60 | $46.07 | +8.1% |
| 2025-07-31 | $1.46 | +32.7% | $45.98 | $44.23 | -3.8% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $1.63 | $1.26 | -22.7% | $12.50B | +1.3% |
| 2025-09-30 | $1.69 | $1.63 | -3.6% | $12.22B | +2.8% |
| 2025-06-30 | $1.10 | $1.46 | +32.7% | $12.27B | +0.6% |
| 2025-03-31 | $1.50 | $1.80 | +20.0% | $11.20B | -5.6% |
| 2024-12-31 | $1.47 | $1.67 | +13.6% | $12.34B | +7.5% |
| 2024-09-30 | $1.50 | $1.80 | +20.0% | $11.89B | +8.4% |
| 2024-06-30 | $1.63 | $2.07 | +27.0% | $12.20B | +8.7% |
| 2024-03-31 | $-4.14 | $-4.40 | -6.3% | $11.87B | — |
| 2023-12-31 | $1.43 | $1.59 | +11.2% | $11.48B | — |
| 2023-09-30 | $1.76 | $2.00 | +13.6% | $10.97B | — |
| 2023-06-30 | $1.98 | $1.75 | -11.6% | $11.23B | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $6.33 | $47.6B | +-1.3% | 16 | high |
| 2027 (E) | $6.19 | $46.6B | +-2.0% | 16 | high |
| 2028 (E) | $6.50 | $47.2B | +1.3% | 16 | medium |
| 2029 (E) | $6.85 | $48.8B | +3.4% | 16 | medium |
| 2030 (E) | $7.20 | $50.5B | +3.5% | 16 | medium |
Frequently asked questions
Has Bristol-Myers Squibb Company beaten earnings estimates?
Bristol-Myers Squibb Company has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of +6.6% over the last 4 quarters.
How does BMY stock react to earnings?
BMY stock has moved an average of +4.0% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Bristol-Myers Squibb Company's revenue growth rate?
Bristol-Myers Squibb Company reported year-over-year revenue growth of +1.3% in its most recent quarter, with EPS growing -24.6% year-over-year.
What is the expected EPS for BMY in 2026?
Analysts expect Bristol-Myers Squibb Company to report EPS of $6.33 for fiscal year 2026, on revenue of $47.6B, based on estimates from 16 analysts.